Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Head and Neck Squamous Cell Cancer: KOL Insight [2017]

Product Code:
596200744
Publication Date:
February 2017
Format:
PDF + PPTX
Price:
€7595

How will immunotherapy continue to shape the HNSCC treatment landscape?

The availability of Merck &Co.’s Keytruda and BMS’ Opdivo has already transformed the second-line treatment of head and neck squamous cell carcinoma (HNSCC) in the US and further immunotherapy approvals are expected to fuel the continuing evolution of the treatment algorithm. KOL’s weigh in on the prospects for expanded use of Keytruda and Opdivo, as well as the potential opportunity for newer immunotherapies such as AstraZeneca’s durvalumab, Merck Group/Pfizer’s avelumab and Tessa Therapeutics’ T-cell therapy TT10. Meanwhile, how will Eli Lilly/Merck Group’s Erbitux secure its market presence as the competitive environment heats up? How are key clinical trials set to shape treatment decisions in HNSCC?

6 US and 6 EU KOLs offer their candid insights on these issues and more

Download sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

Top Takeaways

  • Distinctly different approaches are being adopted by BMS and Merck & Co. in the race to capture the lucrative first-line recurrent/metastatic space. How do KOLs compare and contrast these approaches, and where could durvalumab fit in?
  • Immunotherapy has transformed the second-line treatment of recurrent/metastatic HNSCC. But how do the clinical profiles of Keytruda and Opdivo compare, and how will oncologists choose between them?
  • Could avelumab prove an effective treatment for locally advanced HNSCC? And could nasopharyngeal carcinoma provide an additional niche opportunity for this PD-L1 inhibitor?
  • Combination immunotherapy is seen as a high-risk, high-reward strategy. KOLs rate the potential of such treatment strategies against a backdrop of scarce data and high expectations.
  • The EXTREME regimen is firmly entrenched as the first-line standard of care for recurrent/metastatic HNSCC. But what opportunities and threats lie ahead for Erbitux?
  • Could EBV-specific T cells constitute an effective treatment for nasopharyngeal carcinoma? What potential barriers could curtail the widespread use of TT10 in HNSCC therapy and how could they be mitigated?
  • What place could predictive biomarkers have in guiding the use of immunotherapies in the treatment of HNSCC? Will cost and differential responses restrict the use of immunotherapy to specific patient subgroups in the longer term?
Request sample pages

Back to the top

Quotes

“Pembrolizumab and nivolumab are pretty much interchangeable; [but] the convenience of every three weeks trumps the every two week. It’s also potentially very likely that the payers will also find a preference for one or the other, depending on cost, potentially forcing the clinicians as to which one we choose.”
US Key Opinion Leader

“I think immunotherapy will play a bigger role, and will be integrated into early therapy lines. It could be used in first line and in the curative intent setting, local regional advanced adjuvant or in combination with radiation. Immunotherapy will be at the forefront of development.”
US Key Opinion Leader

Sample of therapies covered

Marketed Therapies

  • Erbitux (cetuximab; Eli Lilly/Merck Group)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo (nivolumab; Bristol-Myers Squibb)

Pipeline Therapies

  • Afatinib (Gilotrif/Giotrif; Boehringer Ingelheim)
  • Durvalumab (MEDI4736; AstraZeneca)
  • Avelumab (PF-06834635; Merck Group/Pfizer)
  • TT10 (EBV specific T cells; Tessa Therapeutics)
  • Plus 3 more - download the full list now >

Sample of KOLs interviewed

KOLs from North America

  • Neal Ready, Associate Professor of Medicine, Member of the Duke Cancer Institute, Duke University School of Medicine, Durham, NC.
  • A. Dimitrios Colevas, Associate Professor of Medicine (Oncology) and Head and Neck Surgery, Stanford University Medical Center, Stanford, CA.
  • Bruce E. Brockstein, Division Head, Hematology/Oncology, Department of Medicine, Medical Director, Kellogg Cancer Center, Highland Park, IL.

KOLs from Europe

  • Caroline Brammer, Consultant in Clinical Oncology, The Clatterbridge Cancer Centre, Bebington, UK.
  • Bernie Foran, Consultant Clinical Oncologist and Honorary Senior Lecturer, Weston Park Hospital Sheffield, UK.
  • Anonymous German KOL, Professor, Division of Hematology and Medical Oncology and Deputy Director, Major University Hospital, Germany.

Plus 4 more - download the full list now >

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.



customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved